면역분석 시장 : 기술, 제품, 시료, 용도, 최종 용도별 예측(2024-2032년)

Global Immunoassay Market size is projected to record 5.3% CAGR from 2024 to 2032 due to rising strides in immunoassay technology and the strong demand for advanced diagnostics. With ongoing innovations, such as more sensitive and specific assays, the demand for sophisticated diagnostic tools is witnessing a surge. Of late, healthcare providers and patients are increasingly seeking accurate and efficient testing methods for various diseases. This growing need for precision in diagnostics coupled with rapid technological progress is creating a fertile ground for the expansion of immunoassay techniques as it continues to cater to the evolving healthcare demands. For instance, in July 2023, Fapon introduced its newest chemiluminescence immunoassay system, the Shine i8000/9000 for the global market during the 2023 AACC exhibition.

The immunoassay industry is classified into technology, product, specimen, application, end-use, and region.

In terms of application, the market share from the oncology segment will undergo a significant upturn by depicting a 6.2% CAGR through 2032, driven by the growing demand for advanced cancer diagnostics and treatment monitoring. With cancer rate on the rise globally, there is a heightened focus on early detection and personalized therapies, where immunoassays play a pivotal role in offering sensitive and specific detection of cancer biomarkers for timely interventions. As the oncology field continues to advance, the demand for immunoassay technologies will soar, reflecting the urgent need for accurate cancer diagnostics and management.

The diagnostic centers end-use segment in the immunoassay industry will experience 6% CAGR up to 2032. This is fueled by the essential role diagnostic labs play in healthcare for offering a wide array of tests for various diseases. The growing demand for accurate and rapid diagnostic tools is accelerating the significance of diagnostic labs as they have the ability to provide efficient and reliable results swiftly, making them a vital component in the healthcare ecosystem. The rising focus on early disease detection and management will further augment the preference for diagnostic labs.

Asia Pacific immunoassay market size will demonstrate a 6.1% CAGR from 2024 to 2032, attributed to the increasing healthcare expenditure, rising prevalence of chronic diseases, and expanding R&D activities. Countries like China and India are witnessing significant growth in the healthcare sector, propelling the demand for immunoassay technologies. With a vast population base and advancing healthcare infrastructure, Asia Pacific will emerge as a significant contributor to the immunoassay industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast parameters
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increase in the prevalence of chronic conditions
    • 3.2.1.2 Advancements in immunoassay technologies
    • 3.2.1.3 Growing demand for point-of-care testing
    • 3.2.1.4 Rising awareness and screening programs
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Stringent regulatory framework
    • 3.2.2.2 Challenges associated with immunoassay
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Reagents & kits
  • 5.2.1 ELISA reagents & kits
  • 5.2.2 ELISPOT reagents & kits
  • 5.2.3 Rapid test reagents & kits
  • 5.2.4 Western blot reagents & kits
  • 5.2.5 Chemiluminescence immunoassay reagents & kits
  • 5.2.6 Immunofluorescence assay reagents & kits
  • 5.2.7 Other reagents & kits
• 5.3 Analyzers/Instruments
  • 5.3.1 Open ended systems
  • 5.3.2 Closed ended systems

Chapter 6 Market Estimates and Forecast, By Technology, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Enzyme-linked immunosorbent assay (ELISA)
• 6.3 Chemiluminescence immunoassay (CLIA)
• 6.4 Radioimmunoassay (RIA)
• 6.5 Immunofluorescence assay (IFA)
• 6.6 Western blotting
• 6.7 ELISpot
• 6.8 Other technologies

Chapter 7 Market Estimates and Forecast, By Specimen, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Blood
• 7.3 Saliva
• 7.4 Urine
• 7.5 Other specimens

Chapter 8 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Infectious diseases
• 8.3 Oncology
• 8.4 Endocrinology
• 8.5 Cardiology
• 8.6 Autoimmune diseases
• 8.7 Therapeutic drug monitoring
• 8.8 Other applications

Chapter 9 Market Estimates and Forecast, By End-Use, 2018-2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals and clinics
• 9.3 Diagnostic centers
• 9.4 Research and academic laboratories
• 9.5 Homecare settings
• 9.6 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Abbott Laboratories
• 11.2 Agilent Technologies, Inc.
• 11.3 Becton Dickinson and Company
• 11.4 Bio-Rad Laboratories, Inc.
• 11.5 Danaher Corporation
• 11.6 F. Hoffmann-La Roche AG
• 11.7 Hologic Inc.
• 11.8 Luminex Corporation
• 11.9 PerkinElmer, Inc.
• 11.10 QIAGEN
• 11.11 Sysmex Corporation
• 11.12 Thermo Fisher Scientific Inc.